Nanobiotix S.A.(NBTX), a late-stage clinical biotechnology company, announced on Monday preclinical data for the Nanoprimer platform in sequence with lipid nanoparticle-delivered recombinant DNA, at the annual meeting of the American Association for Cancer Research (AACR).
The lipid nanoparticle-delivered recombinant DNA (LNP-DNA) therapies previously developed caused rapid hepatic clearance via the mononuclear phagocytic system (MPS), limiting systemic bioavailability and increasing hepatic toxicity.
The company's proprietary Nanoprimer is an early-stage nanotherapeutic platform, developed to increase drug bioavailability and decrease unintended off-target effects in the liver to improve patient outcomes.
When administered intravenously in mouse models with LNP-DNA, it occupied hepatic clearance pathways like MPS to increase bioavailability and target accumulation. This resulted in a reduced hepatic uptake and toxicity, increased circulating levels of LNP-DNA, and mitigated the inflammatory response.
The positive preclinical results indicate that the Nanoprimer has potential broad applications in LNP-DNA formulations, as well as for the delivery of RNA, gene therapies and advanced biologics.
NBTX closed Friday at $33.79, up 4.10%
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.